GENFIT S.A. American Depositary Shares
GNFT Real Time Price USDRecent trades of GNFT by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by GNFT's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
GNFT Revenue by Segment or Geography
New patents grants
-
Patent Title: Methods of treatment of cholestatic diseases Feb. 25, 2025
-
Patent Title: Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation Jan. 28, 2025
-
Patent Title: Non-invasive diagnostic of non-alcoholic steatohepatitis Oct. 01, 2024
-
Patent Title: Pharmaceutical compositions for combination therapy Aug. 06, 2024
-
Patent Title: Methods of treatment of cholestatic diseases Aug. 06, 2024
-
Patent Title: Elafibranor salts Jul. 09, 2024
-
Patent Title: Rorgamma modulators and uses thereof May. 07, 2024
-
Patent Title: Methods of treatment of cholestatic diseases Jan. 02, 2024
-
Patent Title: Methods of treatment of cholestatic diseases Dec. 26, 2023
-
Patent Title: Automated pattern recognition and scoring method of histological images Jun. 13, 2023
-
Patent Title: Pharmaceutical compositions for combination therapy Feb. 28, 2023
-
Patent Title: Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis Dec. 06, 2022
-
Patent Title: Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor Nov. 01, 2022
-
Patent Title: Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent Oct. 25, 2022
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases Aug. 02, 2022
-
Patent Title: Methods for diagnosing and evaluating non-alcoholic steatohepatitis Jun. 28, 2022
-
Patent Title: Methods of treatment of cholestatic diseases May. 17, 2022
-
Patent Title: Pharmaceutical compositions for combination therapy Dec. 07, 2021
-
Patent Title: Methods of treatment of cholestatic diseases Nov. 30, 2021
-
Patent Title: Rorgamma modulators and uses thereof Nov. 02, 2021
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases Aug. 31, 2021
-
Patent Title: Rorgamma modulators and uses thereof Aug. 03, 2021
-
Patent Title: N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2h-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ror-gamma modulators for treating autoimmune diseases Jul. 06, 2021
-
Patent Title: Pharmaceutical compositions for combination therapy Jun. 15, 2021
-
Patent Title: Rorgamma modulators and uses thereof Apr. 27, 2021
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases Feb. 02, 2021
-
Patent Title: Derivatives of 6-substituted triazolopyridazines as rev-erb agonists Oct. 13, 2020
-
Patent Title: Methods of treatment of fibrosis and cancers Oct. 06, 2020
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Jul. 28, 2020
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases May. 19, 2020
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Jul. 16, 2019
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases Nov. 20, 2018
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases Nov. 20, 2018
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases Nov. 06, 2018
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases Nov. 06, 2018
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Jul. 17, 2018
-
Patent Title: Heterocyclic derivatives as rorgamma modulators Feb. 27, 2018
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Oct. 10, 2017
-
Patent Title: Derivatives of 6-substituted triazolopyridazines as rev-erb agonists Mar. 07, 2017
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Mar. 07, 2017
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Dec. 29, 2015
-
Patent Title: 1,3-diphenylpropane derivatives, preparations and uses thereof Aug. 25, 2015
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Nov. 25, 2014
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Jul. 08, 2014
-
Patent Title: Preparation of chalcone derivatives Jul. 01, 2014
-
Patent Title: Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof Jun. 11, 2013
-
Patent Title: Ppar agonist compounds, preparation and uses Jun. 11, 2013
-
Patent Title: Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof Sep. 04, 2012
-
Patent Title: Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof May. 29, 2012
-
Patent Title: Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof Jan. 31, 2012
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to GNFT
Recent picks made for GNFT stock on CNBC
ETFs with the largest estimated holdings in GNFT
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $GNFT stock a Buy, Sell, or Hold?
- What is the price target for $GNFT stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $GNFT stock?
- Who owns the most shares of $GNFT stock?
- What funds own $GNFT stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view GNFT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.